Carbapenems, Monobactams & β-Lactamase Inhibitors
When every other antibiotic has failed and a multidrug-resistant infection is winning, doctors reach for the last β-lactam standing — the carbapenems, the heavy artillery of the antibiotic world. But these are drugs we're desperate to protect, because once bacteria learn to defeat them, we have almost nothing left. This is the story of the strongest β-lactams, and the arms race that surrounds them.
A critically ill patient in intensive care has an infection that has shrugged off drug after drug — a Gram-negative organism carrying enzymes that chew up ordinary penicillins and cephalosporins alike. The team turns to meropenem, a carbapenem, and finally the fever breaks. It worked because carbapenems are the broadest, most enzyme-resistant β-lactams we have — but that very power is why they're locked away for exactly these desperate moments. Squander them, and the next resistant infection may have nothing left to answer it.
Carbapenems: the broadest β-lactams
Carbapenems cover almost everything. The carbapenems — meropenem, imipenem, ertapenem, doripenem — work by the same β-lactam mechanism (blocking PBPs), but their ring resists the great majority of β-lactamase enzymes, so their spectrum is enormous: Gram-positive, Gram-negative, anaerobes, and (except ertapenem) Pseudomonas, including many resistant organisms that defeat other β-lactams. This makes them the drug of choice for severe, multidrug-resistant, or life-threatening infections when the culprit isn't yet known. Two practical notes: imipenem is combined with cilastatin, which blocks a kidney enzyme that would otherwise destroy it; and imipenem in particular can lower the seizure threshold, so care is needed in patients with epilepsy or renal impairment.
Monobactams: the safe-in-allergy option
Aztreonam is the sole monobactam in common use, and it's a specialist. Its spectrum is narrow in an unusual way: it covers ONLY aerobic Gram-negative bacteria (including Pseudomonas) — nothing Gram-positive and no anaerobes. Its great virtue is safety in β-lactam allergy: because of its unique structure, it does NOT cross-react with penicillins or most cephalosporins, so it can be given to a patient with a severe penicillin allergy who still needs Gram-negative cover. Think of aztreonam as the answer to a very specific problem: 'I need to kill a Gram-negative bug, but the patient can't have a penicillin.'
β-lactamase inhibitors: the arms race
Bacteria's favourite weapon against β-lactams is the β-lactamase enzyme, and our counter-weapon is the β-lactamase inhibitor, always given paired with a β-lactam to shield it. The classic inhibitors — clavulanic acid, sulbactam, tazobactam — sacrifice themselves to the enzyme so the real antibiotic survives; they restore activity against many resistant Gram-negatives and are the reason combinations like amoxicillin-clavulanate and piperacillin-tazobactam work so well. But bacteria escalated, evolving carbapenemases that even defeat carbapenems — so a newer generation of inhibitors (avibactam, vaborbactam, relebactam) was created to neutralize those, restoring carbapenems and cephalosporins against some of the most resistant bugs alive. It's an endless chess match: every enzyme meets an inhibitor, every inhibitor meets a new enzyme.
- Carbapenems (meropenem) are the broadest β-lactams — reserve for severe/resistant infections.
- Imipenem is given with cilastatin; imipenem can lower the seizure threshold.
- Aztreonam covers only aerobic Gram-negatives and is SAFE in penicillin allergy (no cross-reactivity).
- β-lactamase inhibitors (clavulanate, tazobactam, avibactam) protect a paired β-lactam.
- Newer inhibitors (avibactam) restore carbapenems against carbapenemase producers.
Carbapenems are a stewardship battleground. They are held in reserve precisely because they work when little else does — but overusing them selects for carbapenem-resistant organisms (CRE), which are among the most feared bacteria in medicine, with pitifully few treatment options. Every carbapenem prescription is therefore a genuine cost to the future: use them when truly needed, de-escalate the moment cultures allow, and never as a lazy 'cover everything' default. Protecting the last drugs is protecting the next patient.
- Using carbapenems as routine broad cover. It breeds carbapenem-resistant organisms (CRE).
- Expecting aztreonam to cover Gram-positives or anaerobes. It's Gram-negative only.
- Giving imipenem carelessly in seizure-prone or renally-impaired patients.
- Forgetting a β-lactamase inhibitor only works when paired with a β-lactam.
Which antibiotic can be safely given to a patient with severe penicillin anaphylaxis who needs Gram-negative cover?
- Carbapenems (meropenem) are the broadest β-lactams — reserved for severe/resistant infections.
- Aztreonam covers aerobic Gram-negatives only and is safe in penicillin allergy.
- β-lactamase inhibitors (clavulanate → avibactam) protect a paired β-lactam against resistance.
- Overusing carbapenems breeds CRE — guard them; de-escalate whenever cultures allow.
- Katzung BG. Basic & Clinical Pharmacology — Beta-Lactam Antibiotics (carbapenems, monobactams, β-lactamase inhibitors).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Carbapenems & monobactams.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Beta-lactam antibiotics.
- IDSA guidance — Treatment of resistant Gram-negative infections; carbapenem stewardship.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — Carbapenems, aztreonam & inhibitors.
